2006-06-19

Anticipated Approval of Latest HIV Drug Will Give Treatment-Experienced Patients the Best Chance Yet to Achieve Undetectable Viral Load


Basel, Switzerland (ots/PRNewswire) -

- Newest HIV Drug Works Better in Combination With FUZEON(R)

The emergence of new HIV treatments, such as boosted proteaseinhibitors (PI), has led to a change in treatment goals for peopleliving with drug-resistant HIV. Up until recently, it has beenreluctantly considered acceptable for treatment-experienced patientsto continue to have a detectable viral load (more than 50 copies ofviral RNA per ml of blood) so long as their immune system can bepreserved. The consequences of remaining detectable are that patientsare likely to accumulate drug resistance, with a consequent loss offuture antiretroviral treatment options, and ultimately leading to adecrease in immune function and clinical disease progression.However, guidelines issued by the US Department of Health and HumanServices (DHHS) recommend establishing maximal viral suppression inthis patient population and support the use of FUZEON with an activeboosted PI to achieve this objective.

The anticipated upcoming US approval of Tibotec's boosted PIdarunavir (TMC114/r) is good news for treatment-experienced patientsfacing drug resistance. It means that they will soon be able tobenefit from potentially two active agents which, when used together,can substantially increase their chances of reaching undetectableviral load.

ots Originaltext: Roche PharmaceuticalsIm Internet recherchierbar: http://www.presseportal.de

Contact:For more information, please contact: Alexander Watson, Ketchum, Office: +44-207-611-3663, E-Mail: alexander.watson@ketchum.com

Roche Pharmaceuticals

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs

News

Anticipated Approval of Latest HIV Drug Will Give Treatment-Experienced Patients the Best Chance Yet to Achieve Undetectable Viral Load

Medizin-News